Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?

Literature DB >> 16520741

Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?

Jonathan C Makielski¹, Carmen R Valdivia.

Abstract

Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2006 PMID： 16520741 PMCID： PMC1617040 DOI： 10.1038/sj.bjp.0706713

Source DB: PubMed Journal: Br J Pharmacol ISSN： 0007-1188 Impact factor: 8.739

22 in total

1. Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.

Authors: T Nagatomo; C T January; J C Makielski
Journal: Mol Pharmacol Date: 2000-01 Impact factor: 4.436

2. Na-H exchange in myocardium: effects of hypoxia and acidification on Na and Ca.

Authors: S E Anderson; E Murphy; C Steenbergen; R E London; P M Cala
Journal: Am J Physiol Date: 1990-12

3. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.

Authors: Yejia Song; John C Shryock; Lin Wu; Luiz Belardinelli
Journal: J Cardiovasc Pharmacol Date: 2004-08 Impact factor: 3.105

4. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.

Authors: Gernot Schram; Liming Zhang; Katayoun Derakhchan; Joachim R Ehrlich; Luiz Belardinelli; Stanley Nattel
Journal: Br J Pharmacol Date: 2004-07-26 Impact factor: 8.739

5. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

Authors: Bernard R Chaitman; Carl J Pepine; John O Parker; Jaroslav Skopal; Galina Chumakova; Jerzy Kuch; Whedy Wang; Sandra L Skettino; Andrew A Wolff
Journal: JAMA Date: 2004-01-21 Impact factor: 56.272

6. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine.

Authors: A I Undrovinas; I A Fleidervish; J C Makielski
Journal: Circ Res Date: 1992-11 Impact factor: 17.367

7. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.

Authors: Bernard R Chaitman; Sandra L Skettino; John O Parker; Peter Hanley; Jaroslav Meluzin; Jerzy Kuch; Carl J Pepine; Whedy Wang; Jeanenne J Nelson; David A Hebert; Andrew A Wolff
Journal: J Am Coll Cardiol Date: 2004-04-21 Impact factor: 24.094

8. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.

Authors: Charles Antzelevitch; Luiz Belardinelli; Andrew C Zygmunt; Alexander Burashnikov; José M Di Diego; Jeffrey M Fish; Jonathan M Cordeiro; George Thomas
Journal: Circulation Date: 2004-08-09 Impact factor: 29.690

9. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.

Authors: Sandra Fredj; Kevin J Sampson; Huajun Liu; Robert S Kass
Journal: Br J Pharmacol Date: 2006-05 Impact factor: 8.739

10. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.

Authors: Lin Wu; John C Shryock; Yejia Song; Yuan Li; Charles Antzelevitch; Luiz Belardinelli
Journal: J Pharmacol Exp Ther Date: 2004-03-18 Impact factor: 4.030

7 in total

1. Voltage-Gated Sodium Channel Phosphorylation at Ser571 Regulates Late Current, Arrhythmia, and Cardiac Function In Vivo.

Authors: Patric Glynn; Hassan Musa; Xiangqiong Wu; Sathya D Unudurthi; Sean Little; Lan Qian; Patrick J Wright; Przemyslaw B Radwanski; Sandor Gyorke; Peter J Mohler; Thomas J Hund
Journal: Circulation Date: 2015-07-17 Impact factor: 29.690

Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?

1. Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.

2. Na-H exchange in myocardium: effects of hypoxia and acidification on Na and Ca.

3. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.

4. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.

5. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

6. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine.

7. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.

8. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.

9. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.

10. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.

1. Voltage-Gated Sodium Channel Phosphorylation at Ser571 Regulates Late Current, Arrhythmia, and Cardiac Function In Vivo.

Review 2. Cardiac electrical remodeling in health and disease.

3. Ranolazine recruits muscle microvasculature and enhances insulin action in rats.

Review 4. Stable angina pectoris: antianginal therapies and future directions.

5. Late Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial Fibrillation.

6. Carbon monoxide effects on human ventricle action potential assessed by mathematical simulations.

7. Hypochlorite-Modified LDL Induces Arrhythmia and Contractile Dysfunction in Cardiomyocytes.